Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company focused on AAV-based cardiovascular gene therapies, reported continued operating losses while maintaining a strong cash position for the quarter and six months ended June 30, 2026.
Total operating expenses were $28.0 million for the quarter and $50.4 million for the first half of 2026, down from $30.7 million and $64.5 million in the prior-year periods, driven mainly by lower general and administrative costs. Net loss was $25.9 million for the quarter and $46.1 million year-to-date, compared with $26.1 million and $58.8 million a year earlier. Net cash used in operating activities was $38.7 million for the first half of 2026.
Cash, cash equivalents and investments in U.S. Treasury securities totaled $234.2 million as of June 30, 2026, with total assets of $254.9 million and stockholders’ equity of $235.1 million. Management estimates these balances are sufficient to fund operations for at least 12 months from issuance of the financial statements, though the company expects to continue incurring substantial losses while advancing its gene therapy pipeline.
Lexeo Therapeutics, Inc. reported second quarter 2026 results and highlighted progress across its genetic cardiology pipeline. For the quarter ended June 30, 2026, the company posted a net loss of $25.9 million, or $0.30 per share, compared with a net loss of $26.1 million, or $0.60 per share, a year earlier. Research and development expenses were $19.0 million versus $14.7 million in the prior-year quarter, while general and administrative expenses declined to $9.0 million from $16.0 million. As of June 30, 2026, Lexeo held $234.2 million in cash, cash equivalents and investments, which it believes will fund operations into 2028.
Operationally, Lexeo finalized the protocol and statistical analysis plan for SUNRISE-FA 2, its open-label pivotal trial of LX2006 for Friedreich ataxia cardiomyopathy under an accelerated approval pathway, and initiated the study with first patient enrollment in June 2026, with topline data expected in the second half of 2027 and a potential BLA submission in the first half of 2028. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim Phase I/II data, while reporting that both LX2006 and LX2020 remain generally well tolerated in treated participants.
State Street Corporation reported beneficial ownership of common stock of Lexeo Therapeutics Inc. in a Schedule 13G filing. State Street, through investment management and trust subsidiaries, reported beneficial ownership of 4,354,775 shares of Lexeo common stock, representing 5.5% of the outstanding class.
The filing states State Street has shared voting power over 4,276,343 shares and shared dispositive power over 4,354,775 shares, with no sole voting or dispositive power. Subsidiaries involved include SSGA Funds Management, Inc., State Street Bank and Trust Company, State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.
Lexeo Therapeutics’ Chief Financial Officer Louis Edward Tamayo reported a mix of stock grant and related share sale. On June 29, 2026, he received an award of 12,000 shares of common stock at no cost as compensation.
On July 1, 2026, he sold 4,641 shares of common stock at a weighted average price of $4.49 per share. A footnote explains this sale was made to cover tax obligations on the release of performance Restricted Stock Units (RSUs), meaning it was a tax-related disposition rather than a discretionary portfolio sale.
Following these transactions, he directly holds 97,024 shares of common stock, which include 89,665 RSUs. Each RSU represents a contingent right to receive one share of Lexeo common stock in the future, typically upon meeting vesting conditions.
Lexeo Therapeutics, Inc. chief operating officer Jose Manuel Otero reported two equity transactions in company common stock. On June 29, he received 12,060 shares at no cost as a grant or award, increasing his direct holdings. On July 1, he sold 4,666 shares at a weighted average price of $4.48 per share to cover tax obligations related to the release of performance Restricted Stock Units, according to the footnotes. After these transactions, he directly holds 137,482 shares, which include 100,621 RSUs, indicating the sale represents a small portion of his overall position.
Lexeo Therapeutics Chief Medical Officer Narinder Pal Bhalla reported a compensation-related stock grant and a tax-related share sale. On June 29, 2026, he received 55,000 shares of common stock as a grant or award. On July 1, 2026, 22,306 shares of common stock were sold at a weighted average price of $4.42 per share to cover tax obligations on the release of performance Restricted Stock Units. After these transactions, he directly held 82,194 shares of common stock, including 49,500 RSUs, each representing a contingent right to receive one share.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported two equity transactions involving the company’s common stock. He received a grant of 67,000 shares of common stock on June 29, 2026 at no cost as a compensation-related award. On July 1, 2026, he sold 25,947 shares at a weighted average price of $4.48 per share, with prices ranging from $4.3402 to $4.7507, specifically to cover tax obligations tied to the release of performance restricted stock units. After the sale, he directly owned 377,817 shares of common stock, which includes 252,130 restricted stock units, indicating he retains a substantial equity position in the company.
LXEO files a Form 144 notice regarding proposed sales of Common Stock. The excerpt lists 4,666 shares in a "Securities To Be Sold" row dated 07/01/2026 and references a Restricted Stock Vesting event on 06/29/2026 tied to compensation. The filing names Fidelity Brokerage Services LLC as a broker/holder.